Skip to main content
Top
Published in:

Open Access 01-02-2025 | Opioids | Research

Efficacy of prophylactic laxatives against opioid-induced constipation: retrospective propensity score matching analysis

Authors: Yuka Okuda, Toshiyuki Kuriyama, Yoshi Tsukiyama, Toshio Shimokawa, Ke Wan, Tomoyuki Kawamata

Published in: Supportive Care in Cancer | Issue 2/2025

Login to get access

Abstract

Purpose

Opioid-induced constipation (OIC) is problematic for patients with cancer receiving opioid therapy. Some guidelines recommend initiating regular laxatives at the same time as opioid analgesics. However, the effectiveness of prophylactic laxatives on OIC has not been widely demonstrated. We therefore examined the incidence of OIC among patients with and without prophylactic laxatives within one week after initiating strong opioid analgesics and the factors associated with the incidence of OIC.

Methods

Eligible patients were adults with cancer for whom strong opioid analgesics were initiated after admission and who remained hospitalized for over a week. Propensity score matching analysis was used to compare outcomes after adjusting for patient background.

Results

In total, 928 patients were enrolled, from which 536 were selected after propensity score matching analysis. The incidence of OIC in patients with prophylactic laxatives was not significantly different from that without prophylactic laxatives (48.1% vs 48.9%, odds ratio (OR) = 0.97, 95% confidence interval (CI): 0.69–1.36). In multivariable logistic analysis, age ≥ 65 years (OR = 1.53, 95% CI: 1.07–2.19) and Eastern Cooperative Oncology Group Performance Status (ECOG PS) ≥ 3 (OR = 1.69, 95% CI: 1.04–2.77) were associated with a higher incidence of OIC.

Conclusion

Prophylactic laxatives did not affect the incidence of OIC in our study. Our results suggest that prophylactic laxatives are not necessarily required when initiating opioid therapy. In addition, we found that age ≥ 65 years and ECOG PS ≥ 3 were associated in our study with a higher incidence of OIC.
Appendix
Available only for authorised users
Literature
1.
go back to reference Wiffen PJ, Wee B, Moore RA (2016) Oral morphine for cancer pain. Cochrane Database Syst Rev 22:4 Wiffen PJ, Wee B, Moore RA (2016) Oral morphine for cancer pain. Cochrane Database Syst Rev 22:4
2.
go back to reference Galligan JJ, Sternini C (2017) Insights into the role of opioid receptors in the GI tract: experimental evidence and therapeutic relevance. Handb Exp Pharmacol 239:363–378CrossRefPubMedPubMedCentral Galligan JJ, Sternini C (2017) Insights into the role of opioid receptors in the GI tract: experimental evidence and therapeutic relevance. Handb Exp Pharmacol 239:363–378CrossRefPubMedPubMedCentral
3.
go back to reference Squeo F, Celiberto F, Ierardi E, Russo F, Riezzo G, D’Attoma B, Di Leo A, Losurdo G (2024) Opioid-induced constipation: old and new concepts in diagnosis and treatment. J Neurogastroenterol Motil 30:131–142CrossRefPubMedPubMedCentral Squeo F, Celiberto F, Ierardi E, Russo F, Riezzo G, D’Attoma B, Di Leo A, Losurdo G (2024) Opioid-induced constipation: old and new concepts in diagnosis and treatment. J Neurogastroenterol Motil 30:131–142CrossRefPubMedPubMedCentral
4.
go back to reference Pappagallo M (2001) Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg 182:11S-18SCrossRefPubMed Pappagallo M (2001) Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg 182:11S-18SCrossRefPubMed
5.
go back to reference Ishihara M, Ikesue H, Matsunaga H, Suemaru K, Kitaichi K, Suetsugu K, Oishi R, Sendo T, Araki H, Itoh Y, Japanese Study Group for the Relief of Opioid-induced Gastrointestinal Dysfunction (2012) A multi-institutional study analyzing effect of prophylactic medication for prevention of opioid-induced gastrointestinal dysfunction. Clin. J. Pain 28:373–81CrossRefPubMed Ishihara M, Ikesue H, Matsunaga H, Suemaru K, Kitaichi K, Suetsugu K, Oishi R, Sendo T, Araki H, Itoh Y, Japanese Study Group for the Relief of Opioid-induced Gastrointestinal Dysfunction (2012) A multi-institutional study analyzing effect of prophylactic medication for prevention of opioid-induced gastrointestinal dysfunction. Clin. J. Pain 28:373–81CrossRefPubMed
6.
go back to reference Harada T, Imai H, Fumita S, Noriyuki T, Gamoh M, Okamoto M, Akashi Y, Kizawa Y, Tokoro A (2021) Opioid-induced constipation in patients with cancer pain in Japan (OIC-J study): a post hoc subgroup analysis of patients with gastrointestinal cancer. Int J Clin Oncol 26:104–110CrossRefPubMed Harada T, Imai H, Fumita S, Noriyuki T, Gamoh M, Okamoto M, Akashi Y, Kizawa Y, Tokoro A (2021) Opioid-induced constipation in patients with cancer pain in Japan (OIC-J study): a post hoc subgroup analysis of patients with gastrointestinal cancer. Int J Clin Oncol 26:104–110CrossRefPubMed
7.
go back to reference Dhingra L, Shuk E, Grossman B, Strada A, Wald E, Portenoy A, Knotkova H, Portenoy R (2013) A qualitative study to explore psychological distress and illness burden associated with opioid-induced constipation in cancer patients with advanced disease. Palliat Med 27:447–456CrossRefPubMed Dhingra L, Shuk E, Grossman B, Strada A, Wald E, Portenoy A, Knotkova H, Portenoy R (2013) A qualitative study to explore psychological distress and illness burden associated with opioid-induced constipation in cancer patients with advanced disease. Palliat Med 27:447–456CrossRefPubMed
8.
go back to reference Argoff CE (2020) Opioid-induced constipation: a review of health-related quality of life, patient burden, practical clinical considerations, and the impact of peripherally acting μ-opioid receptor antagonists. Clin J Pain 36:716–722CrossRefPubMedPubMedCentral Argoff CE (2020) Opioid-induced constipation: a review of health-related quality of life, patient burden, practical clinical considerations, and the impact of peripherally acting μ-opioid receptor antagonists. Clin J Pain 36:716–722CrossRefPubMedPubMedCentral
9.
go back to reference Fine PG, Chen YW, Wittbrodt E, Datto C (2019) Impact of opioid-induced constipation on healthcare resource utilization and costs for cancer pain patients receiving continuous opioid therapy. Support Care Cancer 27:687–696CrossRefPubMed Fine PG, Chen YW, Wittbrodt E, Datto C (2019) Impact of opioid-induced constipation on healthcare resource utilization and costs for cancer pain patients receiving continuous opioid therapy. Support Care Cancer 27:687–696CrossRefPubMed
10.
go back to reference Varrassi G, Banerji V, Gianni W, Marinangeli F, Pinto C (2021) Impact and consequences of opioid-induced constipation: a survey of patients. Pain Ther 10:1139–1153CrossRefPubMedPubMedCentral Varrassi G, Banerji V, Gianni W, Marinangeli F, Pinto C (2021) Impact and consequences of opioid-induced constipation: a survey of patients. Pain Ther 10:1139–1153CrossRefPubMedPubMedCentral
11.
go back to reference Crockett SD, Greer KB, Heidelbaugh JJ, Falck-Ytter Y, Hanson BJ, Sultan S, Committee AGAICG (2019) American gastroenterological association institute guideline on the medical management of opioid-induced constipation. Gastroenterology 156:218–226CrossRefPubMed Crockett SD, Greer KB, Heidelbaugh JJ, Falck-Ytter Y, Hanson BJ, Sultan S, Committee AGAICG (2019) American gastroenterological association institute guideline on the medical management of opioid-induced constipation. Gastroenterology 156:218–226CrossRefPubMed
13.
go back to reference Caraceni A, Hanks G, Kaasa S, Bennett MI, Brunelli C, Cherny N, Dale O, De Conno F, Fallon M, Hanna M, Haugen DF, Juhl G, King S, Klepstad P, Laugsand EA, Maltoni M, Mercadante S, Nabal M, Pigni A, Radbruch L, Reid C, Sjogren P, Stone PC, Tassinari D, Zeppetella G, European Palliative Care Research Collaborative (EPCRC), European Association for Palliative Care (EAPC) (2012) Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol 13:e58-68CrossRefPubMed Caraceni A, Hanks G, Kaasa S, Bennett MI, Brunelli C, Cherny N, Dale O, De Conno F, Fallon M, Hanna M, Haugen DF, Juhl G, King S, Klepstad P, Laugsand EA, Maltoni M, Mercadante S, Nabal M, Pigni A, Radbruch L, Reid C, Sjogren P, Stone PC, Tassinari D, Zeppetella G, European Palliative Care Research Collaborative (EPCRC), European Association for Palliative Care (EAPC) (2012) Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol 13:e58-68CrossRefPubMed
15.
go back to reference Hamano J, Higashibata T, Kessoku T, Kajiura S, Hirakawa M, Oyamada S, Ariyoshi K, Yamada T, Yamamoto Y, Takashima Y, Doki K, Homma M, Mathis BJ, Jono T, Ogata T, Tanaka K, Kasai Y, Iwaki M, Fuyuki A, Nakajima A, Hayashi R, Ando T, Izawa N, Kobayashi Y, Horie Y, Morita T (2024) Naldemedine for opioid-induced constipation in patients with cancer: a multicenter, double-blind, randomized, placebo-controlled trial. J Clin Oncol 10:JCO2400381 Hamano J, Higashibata T, Kessoku T, Kajiura S, Hirakawa M, Oyamada S, Ariyoshi K, Yamada T, Yamamoto Y, Takashima Y, Doki K, Homma M, Mathis BJ, Jono T, Ogata T, Tanaka K, Kasai Y, Iwaki M, Fuyuki A, Nakajima A, Hayashi R, Ando T, Izawa N, Kobayashi Y, Horie Y, Morita T (2024) Naldemedine for opioid-induced constipation in patients with cancer: a multicenter, double-blind, randomized, placebo-controlled trial. J Clin Oncol 10:JCO2400381
16.
go back to reference Tokoro A, Imai H, Fumita S, Harada T, Noriyuki T, Gamoh M, Akashi Y, Sato H, Kizawa Y (2019) Incidence of opioid-induced constipation in Japanese patients with cancer pain: a prospective observational cohort study. Cancer Med 8:4883–4891CrossRefPubMedPubMedCentral Tokoro A, Imai H, Fumita S, Harada T, Noriyuki T, Gamoh M, Akashi Y, Sato H, Kizawa Y (2019) Incidence of opioid-induced constipation in Japanese patients with cancer pain: a prospective observational cohort study. Cancer Med 8:4883–4891CrossRefPubMedPubMedCentral
17.
go back to reference Tokoro A, Imai H, Fumita S, Harada T, Noriyuki T, Gamoh M, Okamoto M, Akashi Y, Kizawa Y (2021) Opioid-induced constipation in patients with cancer pain in Japan (OIC-J Study): a post hoc analysis. J Clin Med 10:4193CrossRefPubMedPubMedCentral Tokoro A, Imai H, Fumita S, Harada T, Noriyuki T, Gamoh M, Okamoto M, Akashi Y, Kizawa Y (2021) Opioid-induced constipation in patients with cancer pain in Japan (OIC-J Study): a post hoc analysis. J Clin Med 10:4193CrossRefPubMedPubMedCentral
18.
go back to reference Kanbayashi Y, Ishizuka Y, Shimizu M, Sawa S, Yabe K, Uchida M (2022) Risk factors for opioid-induced constipation in cancer patients: a single-institution, retrospective analysis. Support Care Cancer 30:5831–5836CrossRefPubMed Kanbayashi Y, Ishizuka Y, Shimizu M, Sawa S, Yabe K, Uchida M (2022) Risk factors for opioid-induced constipation in cancer patients: a single-institution, retrospective analysis. Support Care Cancer 30:5831–5836CrossRefPubMed
19.
go back to reference Mercadante S, Masedu F, Maltoni M, Giovanni D, Montanari L, Pittureri C, Bertè R, Ursini L, Marinangeli F, Aielli F (2018) The prevalence of constipation at admission and after 1 week of palliative care: a multi-center study. Curr Med Res Opin 34:1187–1192CrossRefPubMed Mercadante S, Masedu F, Maltoni M, Giovanni D, Montanari L, Pittureri C, Bertè R, Ursini L, Marinangeli F, Aielli F (2018) The prevalence of constipation at admission and after 1 week of palliative care: a multi-center study. Curr Med Res Opin 34:1187–1192CrossRefPubMed
20.
go back to reference Ducrotté P, Milce J, Soufflet C, Fabry C, (2017) Prevalence and clinical features of opioid-induced constipation in the general population: A French study of 15,000 individuals. United European Gastroenterol J 5:588–600CrossRefPubMed Ducrotté P, Milce J, Soufflet C, Fabry C, (2017) Prevalence and clinical features of opioid-induced constipation in the general population: A French study of 15,000 individuals. United European Gastroenterol J 5:588–600CrossRefPubMed
21.
go back to reference Higashibata T, Kessoku T, Morioka Y, Koretaka Y, Mishima H, Shibahara H, Masuda Y, Ichikawa Y, Nakajima A, Hisanaga T (2023) A nationwide hospital claims database analysis of real-world patterns of laxative use for opioid-induced constipation in Japanese patients with cancer. Pain Ther 12:993–1003CrossRefPubMedPubMedCentral Higashibata T, Kessoku T, Morioka Y, Koretaka Y, Mishima H, Shibahara H, Masuda Y, Ichikawa Y, Nakajima A, Hisanaga T (2023) A nationwide hospital claims database analysis of real-world patterns of laxative use for opioid-induced constipation in Japanese patients with cancer. Pain Ther 12:993–1003CrossRefPubMedPubMedCentral
22.
go back to reference Rosti G, Gatti A, Costantini A, Sabato AF, Zucco F (2010) Opioid-related bowel dysfunction: prevalence and identification of predictive factors in a large sample of Italian patients on chronic treatment. Eur Rev Med Pharmacol Sci 14:1045–1050PubMed Rosti G, Gatti A, Costantini A, Sabato AF, Zucco F (2010) Opioid-related bowel dysfunction: prevalence and identification of predictive factors in a large sample of Italian patients on chronic treatment. Eur Rev Med Pharmacol Sci 14:1045–1050PubMed
24.
go back to reference Clark K, Lam LT, Talley NJ, Phillips JL, Currow DC (2017) Identifying factors that predict worse constipation symptoms in palliative care patients: a secondary analysis. J Palliat Med 20:528–532CrossRefPubMed Clark K, Lam LT, Talley NJ, Phillips JL, Currow DC (2017) Identifying factors that predict worse constipation symptoms in palliative care patients: a secondary analysis. J Palliat Med 20:528–532CrossRefPubMed
25.
go back to reference Dzierżanowski T, Ciałkowska-Rysz A (2015) Behavioral risk factors of constipation in palliative care patients. Support Care Cancer 23:1787–1793CrossRefPubMed Dzierżanowski T, Ciałkowska-Rysz A (2015) Behavioral risk factors of constipation in palliative care patients. Support Care Cancer 23:1787–1793CrossRefPubMed
26.
go back to reference Pehlivan Z, Nural N (2022) Prevalence of constipation in patients undergoing chemotherapy and the effect of constipation on quality of life. Support Care Cancer 30:8019–8028CrossRefPubMed Pehlivan Z, Nural N (2022) Prevalence of constipation in patients undergoing chemotherapy and the effect of constipation on quality of life. Support Care Cancer 30:8019–8028CrossRefPubMed
27.
go back to reference Katakami N, Harada T, Murata T, Shinozaki K, Tsutsumi M, Yokota T, Arai M, Tada Y, Narabayashi M, Boku N (2017) Randomized phase III and extension studies of naldemedine in patients with opioid-induced constipation and cancer. J Clin Oncol 35:3859–3866CrossRefPubMed Katakami N, Harada T, Murata T, Shinozaki K, Tsutsumi M, Yokota T, Arai M, Tada Y, Narabayashi M, Boku N (2017) Randomized phase III and extension studies of naldemedine in patients with opioid-induced constipation and cancer. J Clin Oncol 35:3859–3866CrossRefPubMed
28.
go back to reference Lacy BE, Cangemi DJ (2024) Opioids and the gastrointestinal tract: the role of peripherally active µ-opioid receptor antagonists in modulating intestinal permeability. Am J Gastroenterol 119:1970–1978CrossRefPubMedPubMedCentral Lacy BE, Cangemi DJ (2024) Opioids and the gastrointestinal tract: the role of peripherally active µ-opioid receptor antagonists in modulating intestinal permeability. Am J Gastroenterol 119:1970–1978CrossRefPubMedPubMedCentral
29.
go back to reference Ozaki A, Kessoku T, Tanaka K, Yamamoto A, Takahashi K, Takeda Y, Kasai Y, Iwaki M, Kobayashi T, Yoshihara T, Kato T, Suzuki A, Honda Y, Ogawa Y, Fuyuki A, Imajo K, Higurashi T, Yoneda M, Taguri M, Ishiki H, Kobayashi N, Saito S, Ichikawa Y, Nakajima A (2022) Effectiveness of naldemedine compared with magnesium oxide in preventing opioid-induced constipation: a randomized controlled trial. Cancers (Basel) 14:2112CrossRefPubMed Ozaki A, Kessoku T, Tanaka K, Yamamoto A, Takahashi K, Takeda Y, Kasai Y, Iwaki M, Kobayashi T, Yoshihara T, Kato T, Suzuki A, Honda Y, Ogawa Y, Fuyuki A, Imajo K, Higurashi T, Yoneda M, Taguri M, Ishiki H, Kobayashi N, Saito S, Ichikawa Y, Nakajima A (2022) Effectiveness of naldemedine compared with magnesium oxide in preventing opioid-induced constipation: a randomized controlled trial. Cancers (Basel) 14:2112CrossRefPubMed
30.
go back to reference Erichsén E, Milberg A, Jaarsma T, Friedrichsen M (2016) Constipation in specialized palliative care: factors related to constipation when applying different definitions. Support Care Cancer 24:691–698CrossRefPubMed Erichsén E, Milberg A, Jaarsma T, Friedrichsen M (2016) Constipation in specialized palliative care: factors related to constipation when applying different definitions. Support Care Cancer 24:691–698CrossRefPubMed
31.
go back to reference Tassinari D, Sartori S, Tamburini E, Scarpi E, Tombesi P, Santelmo C, Maltoni M (2009) Transdermal fentanyl as a front-line approach to moderate-severe pain: a meta-analysis of randomized clinical trials. J Palliat Care 25:172–180CrossRefPubMed Tassinari D, Sartori S, Tamburini E, Scarpi E, Tombesi P, Santelmo C, Maltoni M (2009) Transdermal fentanyl as a front-line approach to moderate-severe pain: a meta-analysis of randomized clinical trials. J Palliat Care 25:172–180CrossRefPubMed
32.
go back to reference Tassinari D, Sartori S, Tamburini E, Scarpi E, Raffaeli W, Tombesi P, Maltoni M (2008) Adverse effects of transdermal opiates treating moderate-severe cancer pain in comparison to long-acting morphine: a meta-analysis and systematic review of the literature. J Palliat Med 11:492–501CrossRefPubMed Tassinari D, Sartori S, Tamburini E, Scarpi E, Raffaeli W, Tombesi P, Maltoni M (2008) Adverse effects of transdermal opiates treating moderate-severe cancer pain in comparison to long-acting morphine: a meta-analysis and systematic review of the literature. J Palliat Med 11:492–501CrossRefPubMed
Metadata
Title
Efficacy of prophylactic laxatives against opioid-induced constipation: retrospective propensity score matching analysis
Authors
Yuka Okuda
Toshiyuki Kuriyama
Yoshi Tsukiyama
Toshio Shimokawa
Ke Wan
Tomoyuki Kawamata
Publication date
01-02-2025
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 2/2025
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-025-09154-w

ASH 2024 Annual Meeting Coverage

inMIND supports tafasitamab addition in follicular lymphoma

Combining tafasitamab with lenalidomide and rituximab significantly improves progression-free survival for patients with relapsed or refractory follicular lymphoma.

Featuring the official presentation video

Read more
SPONSORED

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

In this webinar, Professor Martin Dreyling and an esteemed international panel of CAR T-cell therapy experts discuss the latest data on the safety, efficacy, and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL.

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by:
  • Novartis Pharma AG
Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare
Watch now